Skip to main content
. 2020 Feb 20;91(4):418–425. doi: 10.1136/jnnp-2019-322042

Table 1.

Demographics table for participants

Measure Control
(n=37)
Parkinson’s disease
(n=100)
P value
Gender (M:F) 16:21 52:48 ns
Age (years) 66.1 (9.4) 64.5 (7.7) ns
Years of education 17.18 (2.35) 17.04 (2.84) ns
MoCA score (out of 30) 28.6 (1.4) 28.0 (2.0) ns
Cats-and-Dogs score 2.10 (0.58) 1.91 (0.55) ns
Biological motion score 14.68 (9.65) 16.46 (11.49) ns
UPDRS-III 5.5 (4.7) 18.9 (13.3) ***
Pelli-Robson contrast sensitivity 1.81 (0.22) 1.80 (0.16) ns
Binocular LogMAR visual acuity −0.08 (0.23) −0.09 (0.13) ns
D15 hue discrimination total error score 2.22 (6.46) 2.60 (4.93) ns
HADS depression score 1.86 (2.12) 3.78 (2.81) ns
HADS anxiety score 3.97 (3.48) 5.94 (4.12) *
RBDSQ score 1.84 (1.42) 4.14 (2.45) ***
Smell test (Sniffin’ Sticks) 12.43 (2.44) 7.65 (3.21) ***
Disease duration (years) N/A 4.2 (2.5) na
Levodopa equivalent dose (mg) N/A 457 (258) na
Motor deficit dominance (left, right, both) N/A 41: 54: 5 na

Means (SDs) reported.

Sleep Behaviour Disorder Screening Questionnaire. Pelli-Robson: higher score is better contrast sensitivity. Binocular LogMAR: lower score is better visual acuity. D15: lower score is better colour discrimination.

***p<0.001; *p<0.05.

HADS, Hospital Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment; ns, not significant; RBDSQ, REM (rapid eye movement) Sleep Behaviour Disorder Screening Questionnaire; UPDRS-III, Unified Parkinson's Disease Rating Scale part 3.